Has Boone Capital's New HQY Stake Signaled a Strong Buy Opportunity

Key Takeaways

• Boone Capital's $20 million new stake in HealthEquity (HQY) signals a potential conviction play in the specialized healthcare savings sector.
• HealthEquity dominates the Health Savings Account (HSA) market with a ~30% share, driven by sticky employer relationships and high-margin custodial revenue.
• Despite strong growth and analyst "Buy" ratings, HQY faces stiff competition from diversified financial giants and a premium valuation at 35.8x P/E.

Has Boone Capital's New HQY Stake Signaled a Strong Buy Opportunity?

The investment world often scrutinizes the moves of successful hedge funds, seeking clues to undervalued gems or emerging growth stories. Recently, Boone Capital, managed by Daniel Walter Boone IV, initiated a new $20 million position in HealthEquity (NASDAQ: HQY), the leading provider of Health Savings Accounts (HSAs) and other consumer-directed benefits. This move, disclosed in their latest Q4 2025 13F filing (filed February 17, 2026), immediately raises the question: what does Boone Capital see in HQY, and does this signal a compelling opportunity for retail investors?

Boone Capital, with a portfolio value of $318.6 million as of December 31, 2025, is known for its focused approach, with its top five holdings representing nearly 50% of its stock portfolio. The fund's decision to start a new position in HQY, alongside other new stakes in AstraZeneca, TYRA Biosciences, and Wave Life Sciences, suggests a strategic allocation towards specific growth narratives within healthcare and biotech. While the fund was a net seller of stock by -$23 million in the last quarter, the initiation of a significant new position in HQY stands out, indicating a high-conviction bet rather than a broad market play. This fresh capital injection into HealthEquity warrants a deeper dive into the company's fundamentals, market position, and future prospects.

The timing of Boone Capital's entry is particularly interesting, given HQY's recent stock performance. Shares are currently trading at $77.81, up 1.33% today, but have seen a 14.56% decline year-to-date and a 20.12% drop over the past year. This suggests Boone Capital may be buying into a perceived dip, anticipating a rebound based on the company's long-term growth trajectory and market leadership. Understanding the underlying thesis behind this institutional investment requires a thorough examination of HealthEquity's business model, competitive advantages, and the broader landscape of healthcare savings.

What Drives HealthEquity's Business and Market Dominance?

HealthEquity's core strength lies in its dominant position within the rapidly expanding Health Savings Account (HSA) market. The company operates a technology-enabled platform that allows individuals and employers to manage HSAs, Flexible Spending Accounts (FSAs), and Health Reimbursement Arrangements (HRAs). Its business model benefits from two primary revenue streams: administrative fees for managing these accounts and custodial revenue derived from interest earned on the substantial cash balances held within HSAs. This dual-engine revenue model provides both stability and sensitivity to interest rate fluctuations.

With approximately ~30% market share of HSA accounts and over 150,000 employer clients, HealthEquity has established itself as a clear leader. This scale creates significant switching costs for its clients and fosters network effects with health plans, solidifying its competitive moat. The company's brand is virtually synonymous with HSAs, giving it a stronger position compared to more generalized fintech brands like WEX, which also has a health segment. Recent regulatory expansions, allowing direct primary care and pre-deductible telehealth to qualify for HSAs, have significantly broadened the addressable market, poised to accelerate new account openings and Assets Under Management (AUM) growth.

HealthEquity's management has consistently highlighted the strength of its sales engine, even amidst challenging macroeconomic conditions. CEO Scott Cutler noted a "standout fiscal 2026 sales year," driven by record fourth-quarter performance and the addition of over one million new HSA accounts. This growth is fueled by strong open-enrollment execution with enterprise clients, product enhancements leading to higher retail enrollment, and early momentum from newly eligible American families. The company's ability to consistently beat revenue estimates, doing so in eight consecutive quarters, underscores its operational efficiency and market penetration.

What Are the Key Competitive Headwinds and Valuation Concerns for HQY?

While HealthEquity boasts a strong market position, it operates in an increasingly competitive landscape, facing formidable rivals that present significant headwinds. The most potent threat comes from diversified financial behemoths like Fidelity Investments and Optum (part of UnitedHealth Group), which leverage vast existing client bases and bundle HSAs with other services like payroll or brokerage accounts. Fidelity, for instance, uses its HSA offering as a low-cost customer acquisition tool for its broader, more lucrative brokerage and wealth management ecosystem, giving it immense pricing power and a fundamentally different strategic motivation than pure-play HealthEquity.

This dynamic puts constant pressure on HealthEquity's administrative fees, as larger competitors can afford to commoditize HSA services to capture a greater share of a customer's financial life. WEX Inc., another diversified financial technology provider, also competes directly with its Health division. While HQY's specialized focus provides deeper expertise, WEX's broader platform offers cross-selling opportunities and resilience against downturns in any single market. Alight Inc., strong in HR departments of large companies, also presents a challenge with its integrated client relationships, though HealthEquity maintains a stronger financial position with consistent profitability and a healthier balance sheet.

Valuation remains a significant point of contention for HQY. The stock currently trades at a price-to-earnings (P/E) ratio of 35.8x, which is notably high compared to the US Healthcare Providers & Services industry median of 22.4x and peers at 17.2x. This premium valuation suggests that a substantial amount of optimism about future growth is already priced into the shares. While analysts project a fair value of $114.44, suggesting the stock is 32% undervalued, this narrative hinges on aggressive assumptions about future HSA growth, rising margins, and a richer earnings multiple, which could be vulnerable to a weaker labor market or lower interest rates impacting custodial cash yields.

How Has HealthEquity's Recent Financial Performance Stacked Up?

HealthEquity has demonstrated a consistent track record of exceeding analyst expectations, particularly in its recent earnings reports. For Q3 2026, reported on December 3, 2025, the company posted an impressive $1.01 EPS, significantly beating analysts' expectations of $0.83 by 21.69%. This marked a substantial increase from the $0.78 EPS reported in the same quarter last year. Similarly, for Q2 2026 (reported September 2, 2025), HQY delivered $1.08 EPS against an $0.85 estimate, a 27.06% beat. The trend of beating EPS estimates has been strong, with the company surpassing expectations in seven of the last eight quarters.

Revenue performance has been equally robust. In Q3 2026, HealthEquity reported $322.16 million in revenue, exceeding the $320.92 million estimate and representing a 7.2% year-over-year increase. The company has beaten revenue estimates for eight consecutive quarters, showcasing its consistent ability to grow its top line. For the upcoming Q4 2026 earnings, scheduled for March 17, 2026, analysts project an EPS of $0.89 on revenues of $332.85 million, which would represent a 29% year-over-year increase in earnings and 6.7% in revenue.

Despite these strong operational results, the stock's year-to-date decline of 15.06% and a 20.12% drop in total shareholder return over the past year indicate that investors are weighing these gains against valuation concerns and broader market sentiment. Analyst consensus, based on 14 brokerage firms, currently rates HQY as a "Buy" or "Moderate Buy," with an average 1-year price target of $112.00 to $116.50. This implies a significant upside from the current price, suggesting that Wall Street generally remains bullish on HealthEquity's long-term prospects, even as the market has pulled back recently.

What Are the Key Risks and Opportunities for HQY Investors?

Investing in HealthEquity, even with institutional backing like Boone Capital's new stake, comes with a distinct set of risks and opportunities that investors must carefully weigh. On the opportunity side, the long-term growth trajectory of the HSA market remains compelling. The increasing cost of healthcare, coupled with regulatory tailwinds expanding HSA eligibility, creates a structural demand for HealthEquity's services. The company's market leadership, sticky employer relationships, and high-margin custodial revenue stream position it well to capitalize on this expansion. Furthermore, its consistent earnings and revenue beats demonstrate strong operational execution.

However, the risks are equally significant. The intense competition from diversified financial giants like Fidelity and Optum poses a constant threat to pricing power and market share. These larger players can leverage their vast resources and bundled service offerings to commoditize HSA administration, potentially eroding HealthEquity's fee-based revenue streams over the long term. Regulatory changes, particularly those affecting tax-advantaged accounts, could also introduce uncertainty. Moreover, HealthEquity's custodial revenue is sensitive to interest rate fluctuations; a sustained period of lower rates could squeeze margins.

Another concern is the company's premium valuation. While analysts see significant upside, the current P/E ratio of 35.8x leaves little room for error. Any slowdown in new account openings, a dip in AUM growth, or increased operational costs (such as custodial expenses) could lead to a de-rating of the stock. Insider selling activity, with a Q1 2026 buy/sell ratio of 0.33 (net selling), including significant in-kind dispositions by the CEO and other executives in January 2026 at prices around $89.83 to $95.24, also warrants attention, as it can sometimes signal a lack of conviction from those closest to the company.

The Bottom Line

HealthEquity presents a compelling, albeit complex, investment case. Boone Capital's new $20 million stake highlights institutional confidence in the company's long-term potential within the growing healthcare savings market. While HQY's market dominance, consistent financial performance, and favorable industry trends offer a strong bull case, investors must remain vigilant about competitive pressures, its premium valuation, and potential interest rate sensitivities. For those with a long-term horizon and an appetite for growth in the specialized healthcare sector, HealthEquity could be a valuable addition, but careful consideration of its inherent risks is paramount.

Want deeper research on any stock? Try Kavout Pro for AI-powered analysis, smart signals, and more. Already a member? Add credits to run more research.